Literature DB >> 3219235

Enhanced in vitro inhibition of HIV-1 replication by 3'-fluoro-3'-deoxythymidine compared to several other nucleoside analogs.

H Hartmann1, M W Vogt, A G Durno, M S Hirsch, G Hunsmann, F Eckstein.   

Abstract

Nucleoside analogs were synthesized and tested for anti-HIV-1 activity in two in vitro test systems using MT-4 cells and peripheral blood lymphocytes. Cytotoxicity was assessed in both assays and additionally in several human lymphoblastoid cell lines. One analog, 3'-fluoro-3'-deoxythymidine, exhibited higher antiviral potency and slightly higher cytotoxicity than 3'-azido-3'-deoxythymidine. Analogs showing lower cytotoxicity than 3'-azido-3'-deoxythymidine demonstrated reduced antiviral activity. 3'-fluoro-3'-deoxythymidine may become an alternative chemotherapeutic agent because of its high antiretroviral potency. Its toxicity, however, deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3219235     DOI: 10.1089/aid.1988.4.457

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

Review 1.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

2.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rats.

Authors:  F D Boudinot; S G Smith; E D Funderburg; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

Authors:  A-C Jacquard; M-N Brunelle; C Pichoud; D Durantel; S Carrouée-Durantel; C Trepo; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

4.  Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Authors:  E Jurkiewicz; G Hunsmann; J Schäffner; T Nisslein; W Lüke; H Petry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus.

Authors:  M M Mansuri; M J Hitchcock; R A Buroker; C L Bregman; I Ghazzouli; J V Desiderio; J E Starrett; R Z Sterzycki; J C Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

6.  Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.

Authors:  R Koshida; S Cox; J Harmenberg; G Gilljam; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

7.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.

Authors:  R F Schinazi; F D Boudinot; K J Doshi; H M McClure
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine.

Authors:  X B Kong; Q Y Zhu; P M Vidal; K A Watanabe; B Polsky; D Armstrong; M Ostrander; S A Lang; E Muchmore; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  Synthesis and anti-HIV activity of 5-haloethynyl and 5-(1,2-dihalo)vinyl analogues of AZT and FLT.

Authors:  Nicolas Joubert; Franck Amblard; Kimberly L Rapp; Raymond F Schinazi; Luigi A Agrofoglio
Journal:  Tetrahedron       Date:  2008-02-29       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.